← Back to search

Ditto Biosciences

Evolutionary intelligence for autoimmune disease

Y CombinatorWinter 2026ActiveHealthcareDrug Discovery and Delivery

What they do

Problem

Autoimmune diseases lack sufficiently targeted, effective therapies that can safely modulate the immune system.

Solution

The company uses AI to identify and engineer immunomodulatory proteins evolved in parasites (e.g., viruses, ticks, worms) into new autoimmune drug candidates.

Who it's for

Pharmaceutical and biotechnology companies developing autoimmune therapeutics (and eventually clinicians treating autoimmune patients).

Founders

Dennis Sun
Founder

Scientist and operator transforming natural proteins into therapies. Trained in evolutionary and developmental biology at Harvard (AB) and UC Berkeley (PhD). Previously led software teams, product development, and scientific partnerships as Chief of Staff at a $500M biotech. Now building a platform to mine proteins from viruses, ticks, and worms that will become the next blockbuster drugs for autoimmune disease.

Adair Borges
Founder

Entrepreneurial scientist using evolution to build the next generation of therapeutics for autoimmune disease. UCSF-trained PhD with expertise spanning parasitology, virology, and genomics. Published over 50 scientific papers, and is a coinventor on a patent for anti-CRISPR proteins. Former Miller Fellow at UC Berkeley, and previously led a venture creation team at an early stage biotech company. Motivated by a lifelong fascination with parasites.

Emily Weiss
Founder

I'm a molecular and computational biologist working to revolutionize drug discovery for autoimmune disease. At Ditto, I lead the platform for engineering parasite-derived therapeutics. I hold a PhD in microbiology, genomics, and plant genetics, with a focus on sequencing, high-throughput screening, and computational pipeline development. Published in Nature Microbiology and eLife. Previously at Illumina, DuPont, and an early-stage biotech venture team.

Company timeline

Similar startups